PL2849798T3 - Kompozycje oraz sposoby obejmujące chelatowy kompleks oligonukleotydu-polipeptydu - Google Patents

Kompozycje oraz sposoby obejmujące chelatowy kompleks oligonukleotydu-polipeptydu

Info

Publication number
PL2849798T3
PL2849798T3 PL13791618T PL13791618T PL2849798T3 PL 2849798 T3 PL2849798 T3 PL 2849798T3 PL 13791618 T PL13791618 T PL 13791618T PL 13791618 T PL13791618 T PL 13791618T PL 2849798 T3 PL2849798 T3 PL 2849798T3
Authority
PL
Poland
Prior art keywords
methods
chelate complex
polypeptide compositions
oligonucleotide chelate
oligonucleotide
Prior art date
Application number
PL13791618T
Other languages
English (en)
Inventor
Michel Bazinet
Andrew Vaillant
Original Assignee
Replicor Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49581470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2849798(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc. filed Critical Replicor Inc.
Publication of PL2849798T3 publication Critical patent/PL2849798T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
PL13791618T 2012-05-18 2013-05-17 Kompozycje oraz sposoby obejmujące chelatowy kompleks oligonukleotydu-polipeptydu PL2849798T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261648711P 2012-05-18 2012-05-18
US201261695035P 2012-08-30 2012-08-30
PCT/CA2013/050379 WO2013170386A1 (en) 2012-05-18 2013-05-17 Oligonucleotide chelate complex-polypeptide compositions and methods
EP13791618.5A EP2849798B1 (en) 2012-05-18 2013-05-17 Oligonucleotide chelate complex-polypeptide compositions and methods

Publications (1)

Publication Number Publication Date
PL2849798T3 true PL2849798T3 (pl) 2021-10-18

Family

ID=49581470

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13791618T PL2849798T3 (pl) 2012-05-18 2013-05-17 Kompozycje oraz sposoby obejmujące chelatowy kompleks oligonukleotydu-polipeptydu

Country Status (34)

Country Link
US (1) US9492506B2 (pl)
EP (1) EP2849798B1 (pl)
JP (1) JP2015517504A (pl)
KR (1) KR102068109B1 (pl)
CN (1) CN104349793B (pl)
AU (1) AU2013262416B2 (pl)
BR (1) BR112014028654A2 (pl)
CA (1) CA2873529C (pl)
CL (1) CL2014003134A1 (pl)
CO (1) CO7131387A2 (pl)
CR (1) CR20140527A (pl)
CY (1) CY1124345T1 (pl)
DK (1) DK2849798T3 (pl)
DO (1) DOP2014000264A (pl)
EA (1) EA035967B1 (pl)
EC (1) ECSP14027694A (pl)
ES (1) ES2873844T3 (pl)
HR (1) HRP20210840T1 (pl)
HU (1) HUE054875T2 (pl)
IL (1) IL235548B (pl)
LT (1) LT2849798T (pl)
MX (1) MX346239B (pl)
MY (1) MY168778A (pl)
NZ (1) NZ703095A (pl)
PH (1) PH12014502551B1 (pl)
PL (1) PL2849798T3 (pl)
PT (1) PT2849798T (pl)
RS (1) RS62030B1 (pl)
SG (1) SG11201407599SA (pl)
SI (1) SI2849798T1 (pl)
SM (1) SMT202100319T1 (pl)
TW (1) TWI635864B (pl)
WO (1) WO2013170386A1 (pl)
ZA (1) ZA201408674B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2158316T3 (en) 2007-05-11 2015-07-20 Adynxx Inc Gene expression and pain
RU2668136C2 (ru) 2012-05-10 2018-09-26 Эйдинкс, Инк. Композиции для доставки активных ингредиентов
WO2014032176A1 (en) 2012-08-30 2014-03-06 Replicor Inc. Methods for the treatment of hepatitis b and hepatitis d infections
HRP20231400T1 (hr) * 2014-07-10 2024-02-16 Replicor Inc. Kelirani fosforotioirani polimeri nukleinskih kiselina, namijenjeni upotrebi u kombinaciji s inhibitorom hbv polimeraze u liječenju infekcija virusima hepatitisa b i hepatitisa d
CN106661578B (zh) 2014-08-15 2020-08-04 埃迪恩克斯股份有限公司 用于疼痛治疗的寡核苷酸诱饵
MA53674A (fr) * 2018-11-08 2021-07-28 Aligos Therapeutics Inc Polymères oligonucléotidiques inhibant le transport de l'antigène s et procédés
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2024255846A1 (en) * 2023-06-16 2024-12-19 Ractigen Therapeutics Oligonucleotide formulation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2769114B2 (ja) * 1993-10-29 1998-06-25 サイクローン・ファーマシューティカルズ ミニマルｂ型肝炎感染症治療用医薬組成物
UA78726C2 (en) * 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
CA2498777C (en) * 2002-09-13 2015-01-13 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
JP2006519235A (ja) * 2003-02-26 2006-08-24 インターミューン インコーポレイティッド ポリエチレングリコール修飾インターフェロン組成物およびその使用方法
EP1677827B1 (en) * 2003-10-27 2008-12-10 Vertex Pharmaceuticals Incorporated Combinations for hcv treatment
WO2006042418A1 (en) 2004-10-19 2006-04-27 Replicor Inc. Antiviral oligonucleotides
WO2007022642A2 (en) 2005-08-25 2007-03-01 Replicor Inc. Anti-inflammatory molecules and their uses
US7776818B2 (en) * 2005-09-29 2010-08-17 S-Cell Biosciences, Inc. Methods to treat T-cell disorders using TISF
US20090215873A1 (en) 2005-09-29 2009-08-27 Andrew Vaillant Therapeutic Molecules and their Uses
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
WO2009076679A2 (en) * 2007-12-13 2009-06-18 Alnylam Pharmaceuticals Inc. Methods and compositions for prevention or treatment of rsv infection
US8404659B2 (en) 2008-03-07 2013-03-26 Santaris Pharma A/S Pharmaceutical compositions for treatment of MicroRNA related diseases
CA2764683A1 (en) * 2009-05-28 2010-12-02 Joseph Collard Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
US8598334B2 (en) * 2009-10-16 2013-12-03 Glaxo Group Limited HBV antisense inhibitors
CA2855690C (en) * 2010-08-20 2015-08-25 Replicor Inc. Oligonucleotide chelate complexes
WO2014032176A1 (en) 2012-08-30 2014-03-06 Replicor Inc. Methods for the treatment of hepatitis b and hepatitis d infections

Also Published As

Publication number Publication date
SMT202100319T1 (it) 2021-09-14
ECSP14027694A (es) 2015-12-31
US9492506B2 (en) 2016-11-15
EP2849798A4 (en) 2016-03-09
SG11201407599SA (en) 2014-12-30
KR20150013309A (ko) 2015-02-04
CA2873529C (en) 2020-08-18
MY168778A (en) 2018-12-04
CN104349793A (zh) 2015-02-11
DOP2014000264A (es) 2015-01-31
CL2014003134A1 (es) 2015-02-13
JP2015517504A (ja) 2015-06-22
KR102068109B1 (ko) 2020-01-21
HRP20210840T1 (hr) 2021-08-06
AU2013262416A1 (en) 2014-12-18
LT2849798T (lt) 2021-08-10
DK2849798T3 (da) 2021-05-31
CR20140527A (es) 2014-12-15
TWI635864B (zh) 2018-09-21
PT2849798T (pt) 2021-05-18
PH12014502551B1 (en) 2019-10-11
EP2849798A1 (en) 2015-03-25
HUE054875T2 (hu) 2021-10-28
CY1124345T1 (el) 2022-07-22
MX2014014021A (es) 2015-02-10
PH12014502551A1 (en) 2015-01-21
NZ703095A (en) 2016-07-29
EA201401278A1 (ru) 2015-04-30
EP2849798B1 (en) 2021-04-07
AU2013262416B2 (en) 2017-05-11
SI2849798T1 (sl) 2021-08-31
BR112014028654A2 (pt) 2017-10-10
IL235548A0 (en) 2015-01-29
HK1204279A1 (en) 2015-11-13
RS62030B1 (sr) 2021-07-30
IL235548B (en) 2019-07-31
CO7131387A2 (es) 2014-12-01
MX346239B (es) 2017-03-13
WO2013170386A1 (en) 2013-11-21
EA035967B1 (ru) 2020-09-07
ZA201408674B (en) 2016-01-27
US20130309201A1 (en) 2013-11-21
CA2873529A1 (en) 2013-11-21
CN104349793B (zh) 2017-11-10
ES2873844T3 (es) 2021-11-04
TW201408308A (zh) 2014-03-01

Similar Documents

Publication Publication Date Title
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
EP2852602A4 (en) COMPOSITIONS AND METHODS FOR CONJUGATING OLIGONUCLEOTIDES
HUE051744T2 (hu) Kitozánból származtatott készítmények
ZA201408082B (en) Oligonucleotide chelate complex methods
ZA201408674B (en) Oligonucleotide chelate complex-polypeptide compositions and methods
GB2511197B (en) Compositions
GB201315350D0 (en) Methods and compositions
GB201210800D0 (en) Compositions
GB201209244D0 (en) Compositions
GB201315347D0 (en) Methods and compositions
ZA201308892B (en) Compositions and methods
EP2874641A4 (en) COMPOSITIONS INCREASING THE GLUTATHION RATE AND USES THEREOF
GB201201287D0 (en) Compositions
GB201220068D0 (en) Compositions
ZA201502542B (en) Compositions
GB201219962D0 (en) Compositions
GB201219980D0 (en) Compositions
GB201219973D0 (en) Compositions
TWI561248B (en) Peracid-generating compositions
EP2926813A4 (en) METFORMIN-Orlistat COMPOSITIONS
GB201116340D0 (en) Compositions and methods
GB201222702D0 (en) Compositions
GB201218959D0 (en) Compositions
GB201209189D0 (en) Compositions
GB201204102D0 (en) Compositions